Trial Profile
Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Therapeutic Use
- Acronyms PEOPLE
- Sponsors DBV Technologies
- 20 Feb 2024 According to DBV media release, the company to present data from this trial in collaboration with Icahn School of Medicine at Mount Sinai and Beckman Coulter Life Sciences at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C.
- 04 Dec 2022 This trial has been discontinued in Ireland (Date of the global end of the trial: 12-Oct-2022), according to the European Clinical Trials Database record.
- 17 Nov 2022 This trial has been discontinued in Germany (Date of the global end of the trial: 12-Oct-2022), according to the European Clinical Trials Database record.